Biomarkers for kidney diseases and method for using same

Abstract

The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis.

1 . A biomarker for detecting kidney disease, said biomarker is selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof.  
     
     
         2 . The biomarker according to  claim 1 , wherein said kidney disease is acute renal failure.  
     
     
         3 . The biomarker according to  claim 2 , wherein said acute renal failure is result from acute tubular necrosis.  
     
     
         4 . The biomarker according to  claim 1 , wherein said oligonucleotide sequence of annexin A2 is selected from SEQ ID NO: 1 or SEQ ID NO: 11.  
     
     
         5 . The biomarker according to  claim 1 , wherein said amino acid sequence of annexin A2 is selected from SEQ ID NO: 2 or SEQ ID NO:12.  
     
     
         6 . The biomarker according to  claim 1 , wherein said oligonucleotide sequence of S100A6 is selected from SEQ ID NO: 3 or SEQ ID NO: 9.  
     
     
         7 . The biomarker according to  claim 1 , wherein said amino acid sequence of S100A6 is selected from SEQ ID NO: 4 or SEQ ID NO: 10.  
     
     
         8 . The biomarker according to  claim 1 , wherein said variants of annexin A2 or S100A6 has 80% or more than 80% similarity with the amino acid sequence of annexin A2 or S100A6.  
     
     
         9 . The biomarker according to  claim 1 , wherein said derivatives are to modify the 3′ terminal or 5′ terminal of said oligonucleotide sequence or complementary sequence and keeping 70% or more than 70% similarity with the oligonucleotide sequence of annexin A2 or S100A6.  
     
     
         10 . The biomarker according to  claim 1 , wherein said derivatives are to modify the 3′ terminal or 5′ terminal of said oligonucleotide sequence or complementary sequence and keeping 90% or more than 90% similarity with the oligonucleotide sequence of annexin A2 or S100A6.  
     
     
         11 . A biomarker for detecting kidney disease, said biomarker is selected from the oligonucleotide sequence, complementary sequence or derivatives of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 3 or SEQ ID NO: 9, amino acid sequence or derivatives, fragments, variants, antibody of SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 4 or SEQ ID NO: 10 or combinations thereof.  
     
     
         12 . The biomarker according to  claim 11 , wherein said kidney disease is acute renal failure.  
     
     
         13 . The biomarker according to  claim 12 , wherein said acute renal failure is result from acute tubular necrosis.  
     
     
         14 . The biomarker according to  claim 11 , wherein said variants has 80% or more than 80% similarity with the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 4 or SEQ ID NO: 10.  
     
     
         15 . The biomarker according to  claim 11 , wherein said derivatives of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 3 or SEQ ID NO: 9 are to modify the 3′ terminal or 5′ terminal of said oligonucleotide sequence or complementary sequence and keeping 70% or more than 70% similarity with the oligonucleotide sequence.  
     
     
         16 . The biomarker according to  claim 11 , wherein said derivatives of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 3 or SEQ ID NO: 9 are to modify the 3′ terminal or 5′ terminal of said oligonucleotide sequence or complementary sequence and keeping 90% or more than 90% similarity with the oligonucleotide sequence.  
     
     
         17 . An assay kit for kidney disease, comprising: 
 biomarkers which is selected from: the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof.    
     
     
         18 . The kit according to  claim 17 , wherein said kidney disease is acute renal failure.  
     
     
         19 . The kit according to  claim 18 , wherein said acute renal failure is result from acute tubular necrosis.  
     
     
         20 . The kit according to  claim 17 , wherein said oligonucleotide sequence of annexin A2 is selected from SEQ ID NO: 1 or SEQ ID NO: 11.  
     
     
         21 . The kit according to  claim 17 , wherein said amino acid sequence of annexin A2 is selected from SEQ ID NO: 2 or SEQ ID NO:12.  
     
     
         22 . The kit according to  claim 17 , wherein said oligonucleotide sequence of S100A6 is selected from SEQ ID NO: 3 or SEQ ID NO: 9.  
     
     
         23 . The kit according to  claim 17 , wherein said amino acid sequence of S100A6 is selected from SEQ ID NO: 4 or SEQ ID NO: 10.  
     
     
         24 . The kit according to  claim 17 , wherein said kit further comprising secondary antibodies of any one of amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof.  
     
     
         25 . A diagnosis method for kidney disease, comprising the steps of: 
 (a) providing a sample;    (b) providing biomarkers which is selected from: 
 oligonucleotide sequence, complementary sequence or derivatives of SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 3 or SEQ ID NO: 9, amino acid sequence or derivatives, fragments, variants, antibody of SEQ ID NO: 2, SEQ ID NO: 12, SEQ ID NO: 4 or SEQ ID NO: 10, or combinations thereof.;  
   (c) contacting said biomarkers in step (b) with the substance of the sample in step (a), said substance is selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof; and    (d) detecting products of the biomarkers reacting with said substance in step (c).    
     
     
         26 . The method according to  claim 25 , wherein said sample is urine or pathological section.  
     
     
         27 . The method according to  claim 25 , wherein said biomarkers in step (b) is further immobilized on substrate.  
     
     
         28 . The method according to  claim 27 , wherein said substrate is ELISA plate or bio-chip.  
     
     
         29 . The method according to  claim 25 , wherein said substance in step (c) is further labelled by fluorescence before contacting with biomarkers.  
     
     
         30 . The method according to  claim 25 , wherein said method further comprising a step of recognizing antibody with secondary antibody before step (d).  
     
     
         31 . The method according to  claim 25 , wherein said detecting the product in step (d) is by means of enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) or immunofluorescence.  
     
     
         32 . The method according to  claim 25 , wherein said detecting the product in step (d) is by means of reverse-transcription polymerase chain reaction (RT-PCR) or in situ hybridization.  
     
     
         33 . The method according to  claim 25 , wherein said kidney disease is acute renal failure.  
     
     
         34 . The method according to  claim 33 , wherein said acute renal failure is result from acute tubular necrosis.